[HTML][HTML] Efficacy and response biomarkers of apatinib in the treatment of malignancies in China: a review
Z Tian, X Niu, W Yao - Frontiers in Oncology, 2021 - frontiersin.org
Apatinib is a multitarget tyrosine kinase inhibitor marketed in China for the treatment of
advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used …
advanced gastric cancer (GC) and hepatocellular carcinoma (HCC). It has also been used …
Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
In the later-line setting or for patients with PD-L1-negative tumors, immunotherapy-based
regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this …
regimens remain ineffective against advanced triple-negative breast cancer (TNBC). In this …
Vascular endothelial growth factor receptors [VEGFR] as target in breast cancer treatment: current status in preclinical and clinical studies and future directions
M Malekan, MA Ebrahimzadeh - Current Topics in Medicinal …, 2022 - ingentaconnect.com
Breast cancer [BC] is one of the most common cancers among women, one of the leading
causes of a considerable number of cancer-related death globally. Among all procedures …
causes of a considerable number of cancer-related death globally. Among all procedures …
A real-world multicentre retrospective study of low-dose apatinib for human epidermal growth factor receptor 2-negative metastatic breast cancer
T Zeng, C Sun, Y Liang, F Yang, X Yan, S Bao… - Cancers, 2022 - mdpi.com
Simple Summary There are limited treatments for patients with HER2-negative breast
cancer, especially for patients with metastatic breast cancer. This study aimed to observe the …
cancer, especially for patients with metastatic breast cancer. This study aimed to observe the …
[HTML][HTML] Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting
R Zhang, Y Chen, X Liu, X Gui, A Zhu, H Jiang… - Frontiers in …, 2023 - frontiersin.org
Objectives: This study evaluated the efficacy and safety of apatinib (an oral small-molecule
tyrosine kinase inhibitor targeting VEGFR-2) 250 mg combined with chemotherapy in …
tyrosine kinase inhibitor targeting VEGFR-2) 250 mg combined with chemotherapy in …
[HTML][HTML] Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative …
Y Chen, X Wang, F Du, J Yue, Y Si, X Zhao… - Cancer Biology & …, 2023 - ncbi.nlm.nih.gov
Objective: The choice of chemotherapeutic regimen for triple-negative breast cancer (TNBC)
remains controversial. Homologous recombination deficiency (HRD) has attracted …
remains controversial. Homologous recombination deficiency (HRD) has attracted …
The efficiency and safety of low‐dose apatinib combined with oral vinorelbine in pretreated HER2‐negative metastatic breast cancer
JY Huang, XL Chen, XF Xie, L Song, LP Chen… - Cancer …, 2024 - Wiley Online Library
Background Apatinib is an oral small‐molecule tyrosine kinase inhibitor that blocks vascular
endothelial growth factor receptor‐2. Oral vinorelbine is a semisynthetic chemotherapeutic …
endothelial growth factor receptor‐2. Oral vinorelbine is a semisynthetic chemotherapeutic …
[HTML][HTML] The reversal of anti-HER2 resistance in advanced HER2-positive breast cancer using apatinib: two cases reports and literature review
L He, X Shen, Y Liu, L Gao, J Wu, C Yu… - Translational Cancer …, 2022 - ncbi.nlm.nih.gov
Background Human epidermal growth factor receptor 2 (HER2)-targeted treatment has
yielded a notable clinical benefit in patients with HER2-positive breast cancer. However …
yielded a notable clinical benefit in patients with HER2-positive breast cancer. However …
小分子抗血管生成药物在晚期乳腺癌中的 研究进展.
车雅丹， 李丽霞 - … of Practical Medicine/Shiyong Yixue Zazhi, 2023 - search.ebscohost.com
截至2020 年, 乳腺癌已取代肺癌, 成为全球第一大癌, 而晚期乳腺癌的预后却极不理想.
尽管目前仍以化疗为主要的治疗方法, 但由于它的不良反应较强, 且容易出现抗药性 …
尽管目前仍以化疗为主要的治疗方法, 但由于它的不良反应较强, 且容易出现抗药性 …
A Prospective, Single-Arm, Phase II Trial of Apatinib Combined With Nab-Paclitaxel and Carboplatin for The Neoadjuvant Treatment of Triple-Negative Breast Cancer
T Zeng, J Wang, W Li, Y Yang, F Yang, M Yang, C Sun… - 2021 - researchsquare.com
Background: Pathological complete response (pCR) is essential for improvements of
prognosis in triple-negative breast cancer (TNBC). We evaluated the efficacy of apatinib …
prognosis in triple-negative breast cancer (TNBC). We evaluated the efficacy of apatinib …
